The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.
Transgenic mice expressing mutant amyloid precursor proteins (APPs) have provided important new information about the pathogenesis of Alzheimer's disease (AD) histopathology. However, the molecular basis of memory loss in these mice is poorly understood. One of the major impediments has been the difficulty of distinguishing between age-dependent and age-independent behavioral changes. To address this issue we studied in parallel two lines of APP transgenic mice expressing comparable levels of mutant and wild-type human APP. This enabled us to identify age-independent behavioral deficits that were not specifically related to mutant APP expression. When mice with age-independent deficits were eliminated, we detected memory loss in transgenic mice expressing mutant APP (Tg2576 mice) starting at approximately 6 months, which coincided with the appearance of detergent-insoluble Abeta aggregates (Abeta(insol)). Genetically accelerating the formation of Abeta(insol) resulted in an earlier onset of memory decline. A facile interpretation of these results, namely that memory loss and Abeta(insol) were closely connected, was rejected when we extended our analysis to include older mice. No obvious correspondence between memory and Abeta(insol) was apparent in a combined group of old and young mice unless the mice were stratified by age, whereupon inverse correlations between memory and Abeta(insol) became evident. These results suggested that Abeta(insol) is a surrogate marker for small assemblies of Abeta that disrupt cognition and occur as intermediates during Abeta(insol) formation, and they are the first descriptive in vivo data supporting their role in impairing memory. These studies also provide a methodological framework within which to investigate these Abeta assemblies in vivo.
Westerman
Marcus A
MA
Department of Neurology, Center for Clinical and Molecular Neurobiology, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Cooper-Blacketer
Deirdre
D
Mariash
Ami
A
Kotilinek
Linda
L
Kawarabayashi
Takeshi
T
Younkin
Linda H
LH
Carlson
George A
GA
Younkin
Steven G
SG
Ashe
Karen H
KH
D000367:Age Factors; D000375:Aging; D000544:Alzheimer Disease / Q000150:complications / Q000235:genetics / Q000503:physiopathology*; D019943:Amino Acid Substitution; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000818:Animals; D001522:Behavior, Animal; D015415:Biomarkers / Q000032:analysis; D003902:Detergents / Q000737:chemistry; D004195:Disease Models, Animal; D018450:Disease Progression; D006801:Humans; D046911:Macromolecular Substances; D018782:Maze Learning; D008565:Membrane Proteins / Q000096:biosynthesis / Q000235:genetics; D008569:Memory Disorders / Q000209:etiology / Q000473:pathology / Q000503:physiopathology*; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D053764:Presenilin-1; D012995:Solubility; D013997:Time Factors
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D015415:Biomarkers; D003902:Detergents; D046911:Macromolecular Substances; D008565:Membrane Proteins; C508853:PSEN1 protein, human; D053764:Presenilin-1